Loading…
Develops small-molecule kinase inhibitors for cancer, including a next-generation drug for chronic myeloid leukemia.
Develops small-molecule kinase inhibitors for cancer, including a next-generation drug for chronic myeloid leukemia.
Has no approved product, so spending is funded by selling shares, and any income would come from selling an approved drug or from a partnership. Cash runway and trial results decide how easily it can raise more.
Moat: none (IP / patents). Clinical-stage biotech targeting validated pathways with differentiated molecules, but no approved products.
Headquarters: Boulder, Colorado, US · Founded: 2020 · Employees: 60
Size Enliven Therapeutics (ELVN) is a United States Health Care company (Biotechnology) with a market value of $3.62B, the 1412th largest of 3,117 United States companies the cockpit tracks. Shares closed at $49.43 on 6 Nov 2026.
Performance Over six months the shares gained 21.3%, against +7.3% for the median peer and -1.1% for the United States market (cap-weighted) — 8th highest of 21 in its peer set.
Short interest Short interest is 12.7% of the free float (15 Oct 2026).
Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$129,000 | -$263,000 | -$317,000 | -$297,000 | -$215,000 |
| EBITDA | -$124M | -$119M | -$104M | -$83.2M | -$38.6M |
| Net income | -$106M | -$104M | -$89.0M | -$71.6M | -$37.7M |
| Free cash flow | -$67.0M | -$70.5M | -$73.2M | -$61.4M | -$32.7M |
| Capital expenditure | $98,000 | $158,000 | $44,000 | $149,000 | $612,000 |
| Total debt | $1.51M | $399,000 | $0 | $335,000 | $323,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Enliven Therapeutics ELVN | $3.62B | +21% | n/a | n/a | n/a | n/a |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 6.3× | 1.7% |
| Puma Biotechnology PBYI | $426M | +10% | -3% | 13% | 1.5× | 2.8% |
| Ascentage Pharma Group International 6855.HK | $1.39B | -33% | +70% | -220% | 15.5× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ELVN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +21.7% | +0.4% | 3rd highest of 21 |
| 6-month return | +21.3% | +7.3% | 8th highest of 21 |
| Distance from 52-week high | -20.7% | -24.0% | 9th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Enliven Therapeutics ELVN | United States | $3.62B | +21% | n/a | n/a | n/a | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.63B | -7% | +121% | -253% | 49.1× | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | 10.4× | n/a | n/a |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Disc Medicine IRON | United States | $3.50B | +16% | n/a | n/a | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 4.8× | 3.2% | +12.5% |
| AbCellera Biologics ABCL | United States | $3.85B | +149% | +101% | -340% | 51.7× | n/a | n/a |
| Virbac VIRP.PA | France | $3.38B | +5% | +4% | 15% | 2.1× | 6.2% | +9.4% |
| Dyne Therapeutics DYN | United States | $3.37B | +3% | n/a | n/a | n/a | n/a | n/a |
| Hualan Biological Engineering 002007.SZ | China | $3.37B | -15% | -11% | 17% | 5.6× | 16.7% | -1.8% |
| XtalPi 2228.HK | Hong Kong | $3.35B | -34% | +4% | -127% | 26.3× | n/a | n/a |
| Telix Pharmaceuticals TLX.AX | Australia | $3.22B | -6% | +27% | -1% | 3.9× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $4.08B | +46% | +24% | -2,999% | 308.8× | n/a | n/a |
| Denali Therapeutics DNLI | United States | $3.22B | +2% | n/a | -2,488% | 128.0× | n/a | n/a |
| HLB 028300.KS | South Korea | $3.06B | -49% | +29% | -96% | 45.9× | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.01B | -37% | -54% | -6,983% | 6,237.3× | n/a | n/a |
| JOINN Laboratories (China) 6127.HK | Hong Kong | $4.43B | +9% | +17% | -4% | 15.1× | n/a | n/a |
| Adaptive Biotechnologies ADPT | United States | $4.47B | +103% | +50% | -12% | 14.7× | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.93B | +27% | -3% | 16% | 2.8× | -2.0% | +27.4% |
| Zai Lab 9688.HK | Hong Kong | $2.92B | +13% | +5% | -59% | 5.5× | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.91B | +74% | +37% | 21% | 14.2× | n/a | n/a |